Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...

In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of ...

Vuzix Corp (VUZI) stock saw a modest uptick, ending the day at $4.22 which represents a slight increase of $0.11 or 2.68% from the prior close of $4.11. The stock opened at $4.08 and touched a low of ...

“In 2025, the energy sector will be less about barrels of oil and more about...billions of cubic feet of natural gas demand in 2025 and beyond as the technology sector intersects with the energy ...

BTIG analyst Justin Zelin lowered the firm’s price target on Jasper Therapeutics (JSPR) to $64 from $90 and keeps a Buy rating on the shares ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...

Lennar Corp Class A (LEN) stock saw a modest uptick, ending the day at $133.54 which represents a slight increase of $0.40 or 0.30% from the prior close of $133.14. The stock opened at $132.04 and ...

The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...

BTIG raised the firm’s price target on Glaukos (GKOS) to $157 from $149 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models on Medical Technology names ...

BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...

According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...